Research ExplorerPublicationsAmyloid load but not regional glucose metabolism predicts co...

Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population

Standard

Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population. / Frings, Lars; Hellwig, Sabine; Bormann, Tobias; Spehl, Timo S; Buchert, Ralph; Meyer, Philipp T.

In: EUR J NUCL MED MOL I, Vol. 45, No. 8, 07.2018, p. 1442-1448.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Frings, L, Hellwig, S, Bormann, T, Spehl, TS, Buchert, R & Meyer, PT 2018, 'Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population', EUR J NUCL MED MOL I, vol. 45, no. 8, pp. 1442-1448. https://doi.org/10.1007/s00259-018-3983-6

APA

Frings, L., Hellwig, S., Bormann, T., Spehl, T. S., Buchert, R., & Meyer, P. T. (2018). Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population. EUR J NUCL MED MOL I, 45(8), 1442-1448. https://doi.org/10.1007/s00259-018-3983-6

Vancouver

Frings L, Hellwig S, Bormann T, Spehl TS, Buchert R, Meyer PT. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population. EUR J NUCL MED MOL I. 2018 Jul;45(8):1442-1448. https://doi.org/10.1007/s00259-018-3983-6

Bibtex

@article{c6092dd0ece64126b6072d53cf603dc8,
title = "Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population",
abstract = "PURPOSE: The value of imaging regional glucose metabolism with [18F]FDG PET for the prediction of progression from mild cognitive impairment (MCI) to Alzheimer's dementia (AD) is controversial. The predictive value of imaging with [18F]FDG PET was therefore tested and compared with that of imaging beta-amyloid load with [11C]PIB PET in the same memory clinic population of MCI patients.METHODS: Thirty-nine patients with MCI who had undergone [18F]FDG as well as [11C]PIB PET were identified from a single-centre clinical registry. [18F]FDG and [11C]PIB PET images were rated as positive or negative for the presence of regional hypometabolism typical of AD and beta-amyloid deposition, respectively. Raters were blinded to the clinical information. Patients were followed clinically for 2.7 ± 1.2 years after PET. Cox proportional hazards models, adjusted for age and sex, were used to test the predictive value of [18F]FDG PET, [11C]PIB PET, and both in combination.RESULTS: [18F]FDG PET did not significantly predict conversion to AD (p > 0.1). By contrast, models including [11C]PIB PET only (p < 0.05) or both [18F]FDG and [11C]PIB PET (p < 0.05) significantly predicted conversion to AD. The hazard ratio for AD in patients with a positive [11C]PIB scan was 10.2 (95% confidence interval 1.3-78.1). The results were confirmed by analysis of semiquantitative measures using normalized [18F]FDG uptake and [11C]PIB standardized uptake value ratios in AD-typical regions as continuous predictors.CONCLUSION: In contrast to [11C]PIB PET, [18F]FDG PET did not predict conversion from MCI to AD in this clinical patient sample. Therefore, amyloid PET should be preferred for individual prediction and patient counselling in clinical practice.",
keywords = "Aged, Alzheimer Disease, Brain, Cognitive Dysfunction, Female, Fluorodeoxyglucose F18, Glucose, Humans, Male, Middle Aged, Positron-Emission Tomography, Retrospective Studies, Journal Article",
author = "Lars Frings and Sabine Hellwig and Tobias Bormann and Spehl, {Timo S} and Ralph Buchert and Meyer, {Philipp T}",
year = "2018",
month = jul,
doi = "10.1007/s00259-018-3983-6",
language = "English",
volume = "45",
pages = "1442--1448",
journal = "EUR J NUCL MED MOL I",
issn = "1619-7070",
publisher = "Springer",
number = "8",

}

RIS

TY - JOUR

T1 - Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population

AU - Frings, Lars

AU - Hellwig, Sabine

AU - Bormann, Tobias

AU - Spehl, Timo S

AU - Buchert, Ralph

AU - Meyer, Philipp T

PY - 2018/7

Y1 - 2018/7

N2 - PURPOSE: The value of imaging regional glucose metabolism with [18F]FDG PET for the prediction of progression from mild cognitive impairment (MCI) to Alzheimer's dementia (AD) is controversial. The predictive value of imaging with [18F]FDG PET was therefore tested and compared with that of imaging beta-amyloid load with [11C]PIB PET in the same memory clinic population of MCI patients.METHODS: Thirty-nine patients with MCI who had undergone [18F]FDG as well as [11C]PIB PET were identified from a single-centre clinical registry. [18F]FDG and [11C]PIB PET images were rated as positive or negative for the presence of regional hypometabolism typical of AD and beta-amyloid deposition, respectively. Raters were blinded to the clinical information. Patients were followed clinically for 2.7 ± 1.2 years after PET. Cox proportional hazards models, adjusted for age and sex, were used to test the predictive value of [18F]FDG PET, [11C]PIB PET, and both in combination.RESULTS: [18F]FDG PET did not significantly predict conversion to AD (p > 0.1). By contrast, models including [11C]PIB PET only (p < 0.05) or both [18F]FDG and [11C]PIB PET (p < 0.05) significantly predicted conversion to AD. The hazard ratio for AD in patients with a positive [11C]PIB scan was 10.2 (95% confidence interval 1.3-78.1). The results were confirmed by analysis of semiquantitative measures using normalized [18F]FDG uptake and [11C]PIB standardized uptake value ratios in AD-typical regions as continuous predictors.CONCLUSION: In contrast to [11C]PIB PET, [18F]FDG PET did not predict conversion from MCI to AD in this clinical patient sample. Therefore, amyloid PET should be preferred for individual prediction and patient counselling in clinical practice.

AB - PURPOSE: The value of imaging regional glucose metabolism with [18F]FDG PET for the prediction of progression from mild cognitive impairment (MCI) to Alzheimer's dementia (AD) is controversial. The predictive value of imaging with [18F]FDG PET was therefore tested and compared with that of imaging beta-amyloid load with [11C]PIB PET in the same memory clinic population of MCI patients.METHODS: Thirty-nine patients with MCI who had undergone [18F]FDG as well as [11C]PIB PET were identified from a single-centre clinical registry. [18F]FDG and [11C]PIB PET images were rated as positive or negative for the presence of regional hypometabolism typical of AD and beta-amyloid deposition, respectively. Raters were blinded to the clinical information. Patients were followed clinically for 2.7 ± 1.2 years after PET. Cox proportional hazards models, adjusted for age and sex, were used to test the predictive value of [18F]FDG PET, [11C]PIB PET, and both in combination.RESULTS: [18F]FDG PET did not significantly predict conversion to AD (p > 0.1). By contrast, models including [11C]PIB PET only (p < 0.05) or both [18F]FDG and [11C]PIB PET (p < 0.05) significantly predicted conversion to AD. The hazard ratio for AD in patients with a positive [11C]PIB scan was 10.2 (95% confidence interval 1.3-78.1). The results were confirmed by analysis of semiquantitative measures using normalized [18F]FDG uptake and [11C]PIB standardized uptake value ratios in AD-typical regions as continuous predictors.CONCLUSION: In contrast to [11C]PIB PET, [18F]FDG PET did not predict conversion from MCI to AD in this clinical patient sample. Therefore, amyloid PET should be preferred for individual prediction and patient counselling in clinical practice.

KW - Aged

KW - Alzheimer Disease

KW - Brain

KW - Cognitive Dysfunction

KW - Female

KW - Fluorodeoxyglucose F18

KW - Glucose

KW - Humans

KW - Male

KW - Middle Aged

KW - Positron-Emission Tomography

KW - Retrospective Studies

KW - Journal Article

U2 - 10.1007/s00259-018-3983-6

DO - 10.1007/s00259-018-3983-6

M3 - SCORING: Journal article

C2 - 29546632

VL - 45

SP - 1442

EP - 1448

JO - EUR J NUCL MED MOL I

JF - EUR J NUCL MED MOL I

SN - 1619-7070

IS - 8

ER -